|
Delayed
NSE India S.E.
11:48:16 17/11/2026 +03
|
5-day change | 1st Jan Change | ||
| 2,616.10 INR | -0.64% |
|
-2.21% | +28.64% |
| 11-09 | Acucort signs exclusive agreement for Zeqmelit in Canada - launch expected in 2028 | FW |
| 11-06 | Glenmark Pharmaceuticals Limited, Q2 2027 Earnings Call, Nov 06, 2026 |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.64% | -2.21% | +18.46% | +12.41% | +28.64% | +40.09% | +237.41% | +422.16% | +196.18% | 7.91B | ||
| -0.82% | +1.40% | +13.89% | +21.31% | +33.22% | +39.64% | +143.17% | +455.51% | +1,760.76% | 1,275B | ||
| -1.12% | +0.16% | +10.56% | +8.53% | +36.53% | +44.21% | +88.24% | +73.70% | +142.82% | 680B | ||
| -0.16% | +0.43% | +3.20% | +18.08% | +28.91% | +26.76% | +113.01% | +153.01% | +378.63% | 521B | ||
| -0.46% | +1.49% | +7.29% | +14.52% | +24.25% | +41.99% | +71.63% | +9.98% | +74.12% | 389B | ||
| -2.23% | -2.89% | -1.02% | +6.35% | +37.24% | +55.47% | +41.64% | +71.75% | +130.66% | 356B | ||
| -0.63% | +0.39% | +8.70% | +9.40% | +23.18% | +27.62% | +60.52% | +77.12% | +85.69% | 305B | ||
| -0.97% | +0.04% | +12.02% | +20.16% | +0.73% | +2.19% | +35.38% | +61.70% | +220.05% | 287B | ||
| -0.72% | -0.63% | +6.90% | +11.35% | +41.25% | +37.29% | +71.87% | +125.09% | +214.01% | 250B | ||
| -0.30% | -1.03% | +7.29% | +21.12% | +36.53% | +34.04% | +124.88% | +150.53% | +120.50% | 208B | ||
| -1.43% | +3.83% | +9.90% | -3.59% | -13.33% | -9.85% | -59.40% | -25.19% | +145.34% | 185B | ||
| -0.10% | -1.27% | -2.43% | +7.73% | +15.90% | +15.16% | -3.06% | -41.81% | -9.70% | 164B | ||
| -0.15% | -2.37% | +7.61% | +6.34% | +18.62% | +23.02% | +56.79% | +185.56% | +494.44% | 136B | ||
| -0.79% | +1.27% | +5.32% | -1.41% | +16.67% | +34.90% | +23.78% | +6.48% | +11.98% | 129B | ||
| +0.20% | +4.31% | +9.97% | +27.16% | +34.71% | +31.23% | +145.14% | +400.90% | +681.06% | 128B | ||
| -0.38% | +2.43% | +23.98% | +14.84% | +6.43% | -2.06% | +2.50% | -2.83% | +14.00% | 116B | ||
| -0.83% | -0.29% | +3.05% | +3.24% | +4.77% | +6.22% | +35.51% | -1.91% | +0.37% | 102B | ||
| -0.32% | +3.53% | +20.44% | +18.53% | +23.39% | +37.33% | +19.57% | +48.18% | +126.72% | 95.57B | ||
| -3.63% | -19.97% | -1.26% | +239.97% | +629.98% | +769.08% | +181.21% | -8.11% | - | 87.1B | ||
| -0.54% | +2.49% | +15.88% | +6.93% | -10.95% | -13.68% | +49.70% | +76.82% | +562.26% | 76.08B | ||
| Average | -0.80% | -0.01% | +8.99% | +23.15% | +50.83% | +62.03% | +71.98% | +111.93% | +281.57% | 275B | |
| Weighted average by Cap. | -0.82% | +0.63% | +8.93% | +17.51% | +35.85% | +43.39% | +83.97% | +167.71% | +558.42% |
- Stock Market
- Stocks
- GLENMARK Stock
- Sector Glenmark Pharmaceuticals Limited
Select your edition
All financial news and data tailored to specific country editions
















